ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
With
Pfizer
Purpose:
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female ambulatory outpatients being seen in a participating physicians office for routine care,
Patients with a clinical diagnosis of COPD and already being treated with the maintenance therapy with long-acting anticholinergic (Tiotropium (Spiriva® HandiHaler® or Respimat®) at least 1 month and within product label
Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone
You may not be if
Uncooperative patients as judged by the physician
Patients with any conditions excluded as per Country specific package insert
Patients currently enrolled in any clinical trial which requires a change in medication for their respiratory problems.
Clareo Health | ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice
